Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

In the first head-to-head test, Eli Lilly’s Zepbound obesity drug ... while Wegovy users lost 33 pounds. Lilly’s new study is the first randomized clinical trial to demonstrate that Zepbound ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...

Eli Lilly (LLY) and Company announced results from the Phase 3 EMBER-3 study of imlunestrant ... These results were published in The New England Journal of Medicine and will be shared in a ...

Eli Lilly LLY announced results from the phase III EMBER-3 study, which showed that treatment ... demonstrate imlunestrant’s potential as a new oral endocrine therapy option for patients.

Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which dominate the weight loss drug market.

Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the ...

The clearance broadens use of Omvoh, which is part of a slate of new medicines Lilly is counting on to build on its success ...

The medicines may not only suppress appetite but also help curb alcoholism and other addictions. Read more at straitstimes.com.

Eli Lilly LLY0.79%increase ... green up pointing triangle study that has erased as much as $100 billion in market value for the maker of Ozempic. Novo’s latest setback centers on CagriSema ...

A study shows GLP-1 weight-loss drugs reduce Alzheimer’s risk but increase arthritis, kidney, and pancreas issues.